Fineline Cube

Follow:
14422 Articles
GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults
CompanyDrug

GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults

Arcutis Biotherapeutics Receives FDA Approval for ZORYVE (Roflumilast) Cream in Children 2‑5 Years with Atopic Dermatitis
CompanyDrug

Arcutis Biotherapeutics Receives FDA Approval for ZORYVE (Roflumilast) Cream in Children 2‑5 Years with Atopic Dermatitis

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma
CompanyDrug

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease
CompanyDrug

ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease

Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14
CompanyDrug

Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14

Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China
CompanyDeals

Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China

Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B
CompanyDrug

Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B

Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China
CompanyDeals

Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer
CompanyDrug

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14
CompanyDrug

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer
CompanyDrug

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621
CompanyDrug

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621